Quigley 2005 performance
This article was originally published in The Tan Sheet
Quigley's cold remedy segment sales and expansion of its contract manufacturing business helped drive 2005 net sales up 22% to $53.7 mil., the Cold-Eeze marketer reports Feb. 23. The Doylestown, Penn.-based firm attributed cold segment growth to new line extensions, strategic marketing initiatives and increased consumer acceptance. Profit margins from the cold segment products drove a more than seven-fold increase in annual net income to $3.2 mil. Fourth-quarter sales remained flat at $17.7 mil., compared to the prior-year period, due to steady performance across segments...
You may also be interested in...
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
As agency implements testing contract for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.